SCHEMBL5542862

SCHEMBL5542862

[CH2]c1ccccc1Oc1ccc(OC(F)(F)F)cc1Cl

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PNLIP P16233 1/20 0.43
SCN8A Q9UQD0 1/20 0.40
SCN10A Q9Y5Y9 1/20 0.40
SLC6A2 P23975 4/20 0.40
SLC6A3 Q01959 4/20 0.40
SLC6A4 P31645 3/20 0.40
MRGPRX4 Q96LA9 1/20 0.39
CTSC P53634 1/20 0.38
AR P10275 1/20 0.37
EGFR P00533 2/20 0.37
ERBB2 P04626 2/20 0.37
ERBB3 P21860 2/20 0.37
ERBB4 Q15303 2/20 0.37
KIF11 P52732 1/20 0.37
GPR3 P46089 1/20 0.37
SCN9A Q15858 1/20 0.36
PPARD Q03181 1/20 0.36
PPARA Q07869 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28565710 0.82 PNLIP (0.46) PNLIPSCN8ASCN10ASLC6A2SLC6A3
SCHEMBL5547961 0.79 SLC6A4 (0.54) PNLIPSLC6A2SLC6A3SLC6A4KIF11
SCHEMBL5536115 0.78 SLC6A2 (0.40) SLC6A2SLC6A3SLC6A4CTSCKIF11
SCHEMBL5546653 0.78 EGFR (0.44) PNLIPMRGPRX4CTSCAREGFR
SCHEMBL5540166 0.78 SLC6A2 (0.42) PNLIPSLC6A2SLC6A3SLC6A4CTSC
SCHEMBL10825618 0.77 MRGPRX4 (0.48) PNLIPMRGPRX4GPR3SCN9APPARD
SCHEMBL10829853 0.76 TTR (0.55) SLC6A2SLC6A3SLC6A4MRGPRX4
SCHEMBL1047193 0.76 MRGPRX4 (0.45) MRGPRX4KIF11GPR3SCN9APPARD
SCHEMBL2094276 0.76 GPR3 (0.49) CTSCKIF11GPR3SCN9A
SCHEMBL543035 0.76 GPR3 (0.44) SLC6A2SLC6A3MRGPRX4CTSCKIF11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 PNLIP 4829/4885SCN8A 3325/4885SCN10A 4013/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.